1. Jennette JC，Falk RJ，Bacon PA，et al.2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.Arthritis Rheum，2013，65：1-11.

2. Lyons PA，Rayner TF，Trivedi S，et al.Genetically distinct subsets within ANCA-associated vasculitis.N Engl J Med，2012，367：214-223.

3. Stassen PM，Cohen-Tervaert JW，Lems SP，et al. HLADR4，DR13（6）and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener’s granulomatosis. Rheumatology（Oxford），2009，48：622-625.

4. Kain R，Exner M，Brandes R，et al.Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med，2008，14：1088-1096.

5. Chen M，Gao Y，Guo XH，et al.Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. Nat Rev Nephrol，2012，8：476-483.

6. de Lind van Wijngaarden RA，van Rijn L，Hagen EC，et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis：the cause is hidden，but the result is known.Clin J Am Soc Nephrol，2008，3：237-252.

7. Xiao H，Heeringa P，Hu P，et al.Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice.J Clin Invest，2002，110：955-963.

8. Pfister H，Ollert M，Fröhlich LF，et al.Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3（Wegener autoantigen）are pathogenic in vivo. Blood，2004，104：1411-1418.

9. Chen M，Yu F，Zhang Y，et al.Characteristics of Chinese patients with Wegener’s granulomatosis with anti-myeloperoxidase autoantibodies.Kidney Int，2005，68：2225-2229.

10. Chen M，Wang F，Zhao MH.Circulating neutrophil gelatinase associated lipocalin：a useful biomarker for assessing disease activity of ANCA-associated vasculitis.Rheumatology，2009，48：355-358.

11. Xiao H，Heeringa P，Liu Z，et al.The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies.Am J Pathol，2005，167：39-45.

12. Kessenbrock K，Krumbholz M，Schönermarck U，et al. Netting neutrophils in autoimmune small-vessel vasculitis.Nat Med，2009，15：623-625.

13. Xiao H，Schreiber A，Heeringa P，et al.Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol，2007，170：52-64.

14. Schreiber A，Xiao H，Jennette JC，et al.C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis.J Am Soc Nephrol，2009，20：289-298.

15. Berden AE，Ferrario F，Hagen EC，et al.Histopathologic Classification of ANCA-Associated Glomerulonephritis. J Am Soc Nephrol，2010，21：1628-1636.

16. Haas M，Eustace JA.Immune complex deposits in ANCA-associated crescentic glomerulonephritis：a study of 126 cases.Kidney Int，2004，65：2145-2152.

17. Watts R，Lane S，Hanslik T，et al.Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.Ann Rheum Dis，2007，66：222-227.

18. Finkielman JD，Merkel PA，Schroeder D，et al.Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.Ann Intern Med，2007，147：611-619.

19. Stone JH，Merkel PA，Spiera R，et al.Rituximab versus cyclophosphamide for ANCA-associated vasculitis.N Engl J Med，2010，363：221-232.

20. Jones RB，Tervaert JW，Hauser T，et al.Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.N Engl J Med，2010，363：211-220.

21. Jayne DR，Gaskin G，Rasmussen N，et al.Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis.J Am Soc Nephrol，2007，18：2180-2188.

22. Jayne D，Rasmussen N，Andrassy K，et al.A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.N Engl J Med，2003，349：36-44.

23. Pagnoux C，Mahr A，Hamidou MA，et al.Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.N Engl J Med，2008，359：2790-2803.

24. Hiemstra TF，Walsh M，Mahr A，et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis：a randomized controlled trial. JAMA，2010，304：2381-2388.

25. Metzler C，Miehle N，Manger K，et al.Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener’s granulomatosis.Rheumatology（Oxford），2007，46：1087-1091.

26. Stassen PM，Cohen Tervaert JW，Stegeman CA.Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis，2007，66：798-802.

27. Walsh M，Chaudhry A，Jayne D.Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab（CAMPATH-1H）.Ann Rheum Dis，2008，67：1322-1327.

28. Flossmann O，Baslund B，Bruchfeld A，et al.Deoxyspergualin in relapsing and refractory Wegener’s granulomatosis.Ann Rheum Dis，2009，68：1125-1130.

29. Chen M，Yu F，Zhang Y，et al.Antineutrophil cytoplasmic autoantibodies associated vasculitis in older patients. Medicine（Baltimore），2008，87：203-209.

30. Hogan SL，Falk RJ，Chin H，et al.Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis.Ann Intern Med，2005，143：621-631.

31. Pagnoux C，Hogan SL，Chin H，et al.Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis：Comparison of two independent cohorts. Arthritis Rheum，2008，58：2908-2918.